Clinical Trial Update: Phase II Safety Study of 2 Dose Regimens of HepaStem in Patients With ACLF [Phase 2]

View source ↗

Summary

Phase II safety study comparing two dose regimens of HepaStem in patients with Acute-On-Chronic Liver Failure has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• On Chronic Liver Failure

Drugs mentioned

• HepaStem

Snippet

Sponsor: Cellaion SA | Conditions: Acute-On-Chronic Liver Failure | Phase 2 | Status: COMPLETED